Forest’s Faropenem Is “Not Approvable”; Additional Studies Will Take Two Years
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA decision reflects the agency's new position on the need for superiority studies to support the approval of antibiotics, Replidyne says.
You may also be interested in...
Stuck In Reverse: Another Start-up Takes Reverse Merger Route To Public Markets
Deal results in unlikely combination of antbiotics maker Replidyne and device firm Cardiovascular Systems.
Stuck In Reverse: Another Start-up Takes Reverse Merger Route To Public Markets
Deal results in unlikely combination of antbiotics maker Replidyne and device firm Cardiovascular Systems.
Replidyne Shelves Faropenem Program
Potential partners may have been scared off by challenging trial designs, analyst tells “The Pink Sheet” DAILY.